• metastatic glioblastoma (mGB) - 2nd line (L2)
• head and neck cancer squamous cell cancer (HNSCC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• avelumab based treatment
• avelumab alone
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus 5FU plus platin
• Immune checkpoint association
• durvalumab plus tremelimumab

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs HER inhibitor
• vs EGFR inhibitor
• vs cetuximab based chemotherapy
• vs cetuximab plus platin plus 5FU
• vs immune chekpoint inhibitors
• vs anti-CTLA-4
• vs tremelimumab
• vs anti-PD-(L)1
• vs durvalumab based treatment
• vs durvalumab alone
• vs non active control
• vs placebo

  All patients Age < 65y (younger) Age > 75y (older) ECOG 0 ECOG 1 Gender, female Gender, male PD-L1 < 1% PD-L1 > 1% PDL1 < 25% PDL1 >25% smoker (Current) smoker (Former) smoker (never)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

head and neck cancer squamous cell cancer (HNSCC), durvalumab based treatment vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;